Jubilant Therapeutics Announces Oral Presentation of Phase 1 Clinical Results for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential Thrombocythemia …

Jubilant Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing precision therapeutics for ...

Jubilant Therapeutics Announces Oral Presentation of Preliminary Phase 1 Clinical Data for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential ...

Jubilant Therapeutics, Inc., a clinical-stage biopharmaceutical company, advancing precision therapeutics for ...
Fastmarkets

Fastmarkets to reinforce brand normalization for copper concentrates gold and silver credits, not apply separate formula

Fastmarkets has decided to use its existing brand coefficients process for the normalization of gold and silver credits in ...

Chappy's Deep Learning Lecture Room | Part 19: Layer Normalization — What does AI compare within a single piece of data?

A Deeper Look at Batch Normalization.That was a method for finding the mean and variance of the same features across multiple ...

Chapi's Deep Learning Lecture Hall | Part 18: Batch Normalization — Why are the calculation methods different during training and production?

Part 18A Deeper Look at Batch Normalization — Why are the calculation methods different during training and production?Last ...

Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the primary endpoint was met ...

How we classified nearly $900 million in contributions from individuals, companies and PACs

CalMatters analysis of campaign finance contributors helped uncover some of the major influences behind the propositions on ...

Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Po…

(Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of ...

Hf Foods signals 3- to 5-year cross-selling runway as Searay adds mid-teens EBITDA margin in first month

Net revenue increased 4.1% year-over-year to $319.6 million, making our seventh consecutive quarter of year-over-year net revenue growth" (CEO, President & Director Xi Lin), and he tied the mix to ...
Tech Times on MSN

Phase 3 hepatitis delta data drops today at AASLD: Once-monthly combo vs. daily injection

Vir Biotechnology presents Phase 3 ECLIPSE 1 trial data at AASLD 2026 today, testing once-monthly elebsiran plus tobevibart ...
UBS

Beyond mega-cap tech: healthcare's opportunity

Healthcare has spent four years as a market laggard. As the rally broadens and fundamentals improve, could it be entering its ...